Close Menu

HPV

Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.

The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.

The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.

Researchers profiled cervical microbe communities in relation to HPV, HIV, and cervical cytology status, identifying microbial shifts in high-grade lesions and HIV-positive cases.

The firms said that HuaSin obtained exclusive rights to develop a fully automated HPV genotyping assay platform that uses Genomica’s technology.

This Week in PLOS

In PLOS this week: microRNAs linked to brain metastasis risk in lung cancer, effects of Crohn's disease-linked mutation, and more.

Roche Diagnostics had sales of CHF 12.88 billion in 2018. For the fourth quarter, diagnostics sales totaled CHF 3.5 billion, up 10 percent year over year.

A molecular assay used in combination with patient-collected samples had similar accuracy to testing with clinician collected samples. 

Gene expression data revealed two groups of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomas corresponding to distinct survival outcomes.

Simulated population data suggests that the lifetime risk of cervical cancer is lower for women who stop screening after a negative DNA test for oncogenic HPV.

Pages

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.